Exosome Diagnostics and Therapeutics Market to See 39.9% Annual Growth Through 2023

Industry Boosted by Demand for Treatment for Cancer, Infectious Diseases

June 10, 2019

WELLESLEY, Mass., June 10, 2019–The rising prevalence of cancer and infectious diseases are just two factors expected to shape the future of the exosome diagnostics and therapeutics market, according to a report by BCC Research, “Exosome Diagnostics and Therapeutics: Global Markets.”

The market expects to see a compound annual growth rate (CAGR) of 39.9% through 2023, when it could be worth $186.2 million.

Major players in the market include Capricor Therapeutics (NASDAQ: CAPR), Evox Therapeutics, Exopharm (ASX: EX1), Kimera Labs, Panacea Pharmaceuticals and Unicyte.

Research Highlights

  • Reagents will lead the market by growth, with a CAGR through 2023 of 41.4%, followed by software at 39.8% and instruments at 38.4%.
  • Hospitals and diagnostic centers will continue to be the leading end users, with a 2018 value of $18.9 million, followed by cancer institutes at $11.2 million.
  • North America leads the market by size, with a 2018 value of $4.5 million, followed by Europe at $3.2 million and the Asia-Pacific region at $2.3 million.

“Research shows that all fluids in the human body contain exosomes, which can transfer cytoplasmic ingredients to other cells either locally or at distant sites,” notes report author Sathya Durga. “Once they reach the recipient cells, cytoplasmic ingredients can alter their biology. Thus, exosomes are widely being adopted by several end users, including hospitals, diagnostics centers and research institutions.”

Potential Seen for Stem Cell Technologies

Research has shown that mesenchymal stem cells have the ability to reverse acute and chronic kidney injury in different experimental models by paracrine/extracellular mechanisms, the report adds. The exchange of information between the injured cells and stem cells has the potential to be bidirectional, and the vesicles may either transfer transcripts from injured cells to stem cells, or it could go in the opposite direction. Overall, the paracrine hypothesis of MSC action has altered the outlook of the beneficial use of MSCs in regenerative medicine.

Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.

Exosome Diagnostics and Therapeutics: Global Markets( BIO149C )
Publish Date: May 2019    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.